Clinical trial
A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic…
NCT01227278 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT01227278 |
|---|---|
| Title | A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
| Official title | A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia |
| Lead sponsor | MedImmune LLC, Industry |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Biological, Other |
| Interventions | Placebo, Benralizumab 100 mg |
| Enrollment | 421 |
| Start date | Nov 1, 2010 |
| Primary completion | Jan 1, 2013 |
| Completion | Jul 1, 2013 |
| First posted | Oct 25, 2010 |
| Last update posted | Oct 5, 2016 |
| Countries | Canada, Denmark, Germany, Poland, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: